Cocaine Dependence Clinical Trial
Official title:
Cocaine Dependence, Metabotropic Glutamate Receptor Subtype 5 (mGluR5) Density, Genetics and Craving
Objective:
Cocaine addiction continues to be an important public health problem with over 1.7 million
users in the US alone. Cocaine addiction is characterized by compulsive drug use despite
adverse consequences and high rates of relapse during periods of abstinence. Cocaine
addiction may be mediated by neuroadaptations in reward-related learning and memory processes
in the mesocorticolimbic dopamine system and glutamatergic corticolimbic circuitry.
Metabotropic glutamate subtype 5 receptors (mGluR5) likely play essential roles in mediating
some of the actions of drugs of abuse. Animal studies have shown that mGluR5 knock-out or
blockade reduces self-administration of cocaine and cocaine-induced hyper-locomotion.
However, to what extent mGluR5 are involved in the pathophysiology of cocaine addiction in
humans is currently unknown, partly due to the lack of suitable methods to reliably quantify
mGluR5 in the living human brain.
This protocol aims to determine whether the density of mGluR5 in brain is altered in
participants with cocaine addiction compared to healthy controls using positron emission
tomography (PET) and the recently developed radiotracer for mGluR5, [18F]SP203. We also aim
to determine whether this density is related to genotype, history of cocaine use, and/or
craving for cocaine.
Study Population:
The study populations will consist of healthy adults with no history of substance abuse and a
matched group of healthy current primary cocaine dependent male and female participants
(20-50 years old.; N=40/group).
Design:
Density of mGluR5 will be measured in cocaine dependent participants and healthy adults
volunteers with PET and (18F)SP203, a radioligand with specificity for mGluR5. All
participants will undergo genotyping to identify normal or variant mGluR5 gene associated
with drug abuse. The intensity of craving for cocaine will be assessed while watching a video
about cocaine use.
Outcome measures:
Density of mGluR5 will be compared between cocaine dependent participants and healthy
controls. In addition, correlation among the genetic polymorphism, the craving response, and
the density of mGluR5 will be determined.
Objective:
Cocaine addiction continues to be an important public health problem with over 1.7 million
users in the US alone. Cocaine addiction is characterized by compulsive drug use despite
adverse consequences and high rates of relapse during periods of abstinence. Cocaine
addiction may be mediated by neuroadaptations in reward-related learning and memory processes
in the mesocorticolimbic dopamine system and glutamatergic corticolimbic circuitry.
Metabotropic glutamate subtype 5 receptors (mGluR5) likely play essential roles in mediating
some of the actions of drugs of abuse. Animal studies have shown that mGluR5 knock-out or
blockade reduces self-administration of cocaine and cocaine-induced hyper-locomotion.
However, to what extent mGluR5 are involved in the pathophysiology of cocaine addiction in
humans is currently unknown, partly due to the lack of suitable methods to reliably quantify
mGluR5 in the living human brain.
This protocol aims to determine whether the density of mGluR5 in brain is altered in
participants with cocaine addiction compared to healthy controls using positron emission
tomography (PET) and the recently developed radiotracer for mGluR5, [18F]SP203. We also aim
to determine whether this density is related to genotype, history of cocaine use, and/or
craving for cocaine.
Study Population:
The study populations will consist of healthy adults with no history of substance abuse and a
matched group of healthy current primary cocaine dependent male and female participants
(20-55 years old.; N=40/group).
Design:
Density of mGluR5 will be measured in cocaine dependent participants and healthy adults
volunteers with PET and (18(F)SP203, a radioligand with specificity for mGluR5. All
participants will undergo genotyping to identify normal or variant mGluR5 gene associated
with drug abuse. The intensity of craving for cocaine will be assessed while watching a video
about cocaine use.
Outcome measures:
Density of mGluR5 will be compared between cocaine dependent participants and healthy
controls. In addition, correlation among the genetic polymorphism, the craving response, and
the density of mGluR5 will be determined.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04994821 -
tDCS to Reduce Craving in Cocaine Addiction- Phase 2 Study
|
Phase 2 | |
Completed |
NCT01601743 -
Exercise as a Behavioral Treatment for Cocaine Dependence
|
N/A | |
Completed |
NCT01402492 -
Cocaine Use Reduction With Buprenorphine
|
Phase 2/Phase 3 | |
Completed |
NCT01176591 -
HBPL Study of the Impact of the NK1 Antagonist Aprepitant
|
Phase 2 | |
Completed |
NCT00880997 -
The Efficacy of Doxazosin for Cocaine Users
|
Phase 1 | |
Completed |
NCT00566969 -
Cocaine Withdrawal and Pharmacotherapy Response
|
N/A | |
Completed |
NCT00585520 -
Sex Differences in Progesterone Effects on Responses to Stress and Drug Cues
|
Phase 1 | |
Completed |
NCT00368290 -
Modafinil Treatment for Cocaine Dependence and HIV High-Risk Behavior
|
Phase 2 | |
Completed |
NCT00385801 -
Study of the Effects of Risperdal Consta on Brain Reward Circuitry Function, Craving and Cocaine Use in Active Cocaine Dependence
|
Phase 2 | |
Completed |
NCT00322309 -
Efficacy of Mirtazapine in Depressed Cocaine Dependent Subjects
|
Phase 2 | |
Completed |
NCT00842517 -
Long Term Maintenance of Drug Abstinence
|
Phase 1 | |
Completed |
NCT00167245 -
Topiramate for Alcohol and Cocaine Dependence
|
Phase 2 | |
Not yet recruiting |
NCT05974202 -
rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder
|
Phase 2 | |
Completed |
NCT04411914 -
Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid
|
Phase 1 | |
Active, not recruiting |
NCT03266939 -
Rebalancing the Serotonergic System in Cocaine Dependence
|
Phase 1 | |
Completed |
NCT02563769 -
Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study
|
Phase 1 | |
Recruiting |
NCT06159387 -
Randomized, Double-blind, Placebo-controlled Cannabis Extract x Placebo for Cocaine Addicts
|
Phase 4 | |
Terminated |
NCT02935101 -
Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants
|
Phase 2 | |
Completed |
NCT02018263 -
Validation of a Remote Wireless Sensor Network (WSN) Approach to the Individualized Detection of Cocaine Use in Humans
|
Phase 1 | |
Completed |
NCT01573273 -
Oxytocin in Cocaine Dependence
|
N/A |